Plerixafor for mobilization of blood stem cells in autologous transplantation: an update

Abstract

Plerixafor added to G-CSF is superior than G-CSF alone for mobilization of CD34(+) cells. This combination is also efficient in patients who have failed a previous mobilization attempt with other methods or in patients with risk factors for poor mobilization. Addition of plerixafor to G-CSF or chemotherapy plus G-CSF mobilization in patients who appear to mobilize poorly is under active investigation and algorithms for a preemptive use of this expensive agent have been proposed. Grafts collected after plerixafor appear to contain more lymphoid cells than the grafts collected without it. Whether this affects post-transplant outcomes such as immune reconstitution and risk of relapse needs to be evaluated.

BMP2 Regulation of CXCL12 Cellular, Temporal, and Spatial Expression Is Essential During Fracture Repair

“…Furthermore, AMD3100, although largely characterized as a CXCR4 antagonist, has been shown to bind CXCR7 with allosteric agonist (reviewed in Jantunen and colleagues (46) ). Unfortunately, we could not find a reliable antibody to assess the expression pattern of CXCR7 during fracture and in BMP2 mutants.…”

“…Although most of the studies report that CXCR7 represents a "decoy" receptor functioning as scavenging for CXCL12, recent studies have reported that CXCR7 may induce some signaling (reviewed in Jantunen and colleagues (46) ). Furthermore, AMD3100, although largely characterized as a CXCR4 antagonist, has been shown to bind CXCR7 with allosteric agonist (reviewed in Jantunen and colleagues (46) ). Unfortunately, we could not find a reliable antibody to assess the expression pattern of CXCR7 during fracture and in BMP2 mutants.…”

The hematopoietic system in the context of regenerative medicine

“…The non-invasiveness and ease with which mPB could be collected (compared to bone marrow harvest), and the discovery that HSC were present at higher frequency in these mobilized products than in steady-state bone marrow quickly led multiple laboratories/centers around the world to begin replacing bone marrow with mPB in the clinical setting [114–119]. Indeed, the use of mPB as an HSC source has dramatically increased over the past 15 years or so, and now accounts for ~75% of HSC transplants from unrelated adult donors [104] and ~99% of autologous HSC transplants [120]. …”

Mobilization of hematopoietic progenitor cells for autologous transportation: consensus recommendations

“…1,2 Mobilization and collection are crucial steps in this procedure, which aim not only at obtaining enough stem cells for transplantation but also at minimizing the number of apheresis sessions, reducing the risk of complications, preventing failure and optimizing resource allocation. 3 The choice of the mobilization regimen should take into account factors such as efficacy, safety, convenience and cost-effectiveness.…”